GLX Analytix
Copenhagen
About GLX Analytix
At GLX Analytix, we combine a new, proprietary class of blood biomarker with AI to bring personalized medicine to your healthcare. We envision a future where patients are diagnosed earlier, empowered to monitor themselves, and treatment plans are optimized. We aim to improve lives all over the world. GLX Analytix is an Industrial Partner to Harvard Medical / Wyss Diagnostic Accelerator and Winner of Roche Future of Healthcare Award "...this approach has a clear potential to improve the lives of patients all over the world.” - Dr. Tim M. Jaeger, Global Head of Diagnostics Information Solutions, Roche
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Last round: Series Unknown (Oct 2024)
- Website: glxanalytix.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/glx-analytix-2203378 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.